Dados do Trabalho

Título

EGFR MUTATIONS AND PD-L1 EXPRESSION IN EARLY-STAGE NON–SMALL-CELL LUNG CANCER: REAL-WORLD DATA FROM A SINGLE CENTER IN BRAZIL.

Introdução

Targeted and immunotherapies are currently moving towards early-stage settings for non-small cell lung cancer (NSCLC) patients. Data about predictive biomarkers are scarce in this scenario.

Objetivo

The present study aimed to describe the frequency of EGFR mutations and PD-L1 expression in early-stage non-squamous NSCLC patients from a single Brazilian center.

Método

We retrospectively evaluated a series of NSCLC diagnosed at an early-stage (IB to IIIA – AJCC 7th edition) at a Brazilian cancer center (n=302). EGFR mutational status was assessed in FFPE tumor tissues using distinct methodologies (NGS, Cobas, or Sanger sequencing). PD-L1 expression was evaluated by immunohistochemistry (clone 22C3) and reported as Tumor Proportion Score (TPS), categorized as < 1%, 1-49%, and ≥ 50%. We evaluated the association between EGFR mutational status and PD-L1 expression with sociodemographic and clinicopathological parameters by Fisher’s test, qui-square test, and logistic regression. Survival analysis was assessed by the Kaplan-Meier method and Cox regression model. This is an externally sponsored research (ESR) supported by AstraZeneca do Brasil.

Resultado

EGFR mutations were detected in 17.3% (n=48) of cases, and they were associated with female sex, never smokers, and longer overall and event-free survival. PD-L1 positivity was observed in 36.7% (n=69) of the cases [TPS 1-49% n=44(23.4%); TPS ≥50% n=25(13.3%)]. PD-L1 positivity was associated with smoking, weight loss, and increased disease staging (IIB/IIIA).

Conclusão

In conclusion, in this series of Brazilian early-stage NSCLC patients, the frequency of EGFR mutations was 17.3% and the PD-L1 positivity 36.7% of cases. These results can help the tailored treatment in early-stage NSCLC patients.

Palavras-chave

Lung cancer, Precision Medicine, Biomarkers